FIGURE 5.

Annualized LS mean change from baseline of whole brain volume, hippocampal volume, and ventricular volumes as measured by volumetric MRI from AMARANTH and DAYBREAK‐ALZ studies.

Significantly greater decrease in whole brain volume was observed for lanabecestat 20 mg and 50 mg groups in (A) AMARANTH and for lanabecestat 50 mg group in (B) DAYBREAK‐ALZ compared to placebo. Significantly greater decrease in hippocampal volume was observed for lanabecestat 20 mg and 50 mg groups compared to placebo in (C) AMARANTH, but not in (D) DAYBREAK‐ALZ. No significant differences in ventricular enlargement were observed between either of the lanabecestat groups and placebo (E, F). P values nominal and not adjusted for multiplicity. Hippocampal volumes figure reprinted with permission from Wessels et al. ⁵ Abbreviations: LS, least squares; pbo, placebo; SE, standard error; vMRI, volumetric magnetic resonance imaging.